Search Result

Results for "

psychiatric+disorders

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (17) Akt (1) Amino Acid Oxidase (1) Autophagy (7) Biochemical Assay Reagents (2) Calcium Channel (4) Carbonic Anhydrase (1) Casein Kinase (1) Cholinesterase (ChE) (1) COX (1) CRFR (1) Cytochrome P450 (3) Dopamine Receptor (14) EAAT (1) Endogenous Metabolite (9) Enterovirus (4) ERK (1) GABA Receptor (9) Glucocorticoid Receptor (1) GPR6 (1) GSK-3 (4) HCN Channel (2) Histamine Receptor (5) iGluR (18) IPK Superfamily (1) Isotope-Labeled Compounds (9) mAChR (13) mGluR (1) nAChR (1) Neurokinin Receptor (1) Neurotensin Receptor (4) Opioid Receptor (1) Oxytocin Receptor (2) PACAP Receptor (1) Phosphodiesterase (PDE) (3) PI3K (1) PKA (1) Potassium Channel (6) Radionuclide-Drug Conjugates (RDCs) (1) Reference Standards (9) Ser/Thr Protease (1) Serotonin Transporter (1) Sigma Receptor (1) TNF Receptor (1) Trk Receptor (2)
By Research Areas:	Cancer (12) Cardiovascular Disease (3) Infection (5) Inflammation/Immunology (5) Metabolic Disease (11) Neurological Disease (91)

By Targets:

5-HT Receptor (17)

Akt (1)

Amino Acid Oxidase (1)

Autophagy (7)

Biochemical Assay Reagents (2)

Calcium Channel (4)

Carbonic Anhydrase (1)

Casein Kinase (1)

Cholinesterase (ChE) (1)

COX (1)

CRFR (1)

Cytochrome P450 (3)

Dopamine Receptor (14)

EAAT (1)

Endogenous Metabolite (9)

Enterovirus (4)

ERK (1)

GABA Receptor (9)

Glucocorticoid Receptor (1)

GPR6 (1)

GSK-3 (4)

HCN Channel (2)

Histamine Receptor (5)

iGluR (18)

IPK Superfamily (1)

Isotope-Labeled Compounds (9)

mAChR (13)

mGluR (1)

nAChR (1)

Neurokinin Receptor (1)

Neurotensin Receptor (4)

Opioid Receptor (1)

Oxytocin Receptor (2)

PACAP Receptor (1)

Phosphodiesterase (PDE) (3)

PI3K (1)

PKA (1)

Potassium Channel (6)

Radionuclide-Drug Conjugates (RDCs) (1)

Reference Standards (9)

Ser/Thr Protease (1)

Serotonin Transporter (1)

Sigma Receptor (1)

TNF Receptor (1)

Trk Receptor (2)

By Research Areas:

Cancer (12)

Cardiovascular Disease (3)

Infection (5)

Inflammation/Immunology (5)

Metabolic Disease (11)

Neurological Disease (91)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12708

Chlorpromazine Maximum Cited Publications 128 Publications Verification	Dopamine Receptor Cytochrome P450 Autophagy 5-HT Receptor	Cardiovascular Disease Neurological Disease Cancer
Chlorpromazine is an orally active, blood-brain barrier-transparent antipsychotic agent that effectively antagonises D2 dopamine receptors and 5-HT_2A, which is widely used in schizophrenia and other psychiatric disorders. Chlorpromazine exerts anti-cancer activity through a variety of pathways, including anti-proliferation, induction of autophagy and cycle arrest (G2-M phase), inhibition of cytochrome c oxidase (CcO), inhibition of tumour growth and metastasis, and inhibition of tumour immune escape. Chlorpromazine also blocks hNa_v1.7 channels (IC₅₀=25.9 μM; concentration-dependent) and HERG potassium channels (IC₅₀=21.6 μM), which has potential for analgesic and cardiac arrhythmic studies. Chlorpromazine also can inhibit clathrin-mediated endocytosis .

HY-B0407A

Chlorpromazine hydrochloride Maximum Cited Publications 128 Publications Verification	Dopamine Receptor Autophagy Cytochrome P450 5-HT Receptor	Cardiovascular Disease Neurological Disease Cancer
Chlorpromazine hydrochloride is an orally active, blood-brain barrier-transparent antipsychotic agent that effectively antagonises D2 dopamine receptors and 5-HT_2A, which is widely used in schizophrenia and other psychiatric disorders. Chlorpromazine hydrochloride exerts anti-cancer activity through a variety of pathways, including anti-proliferation, induction of autophagy and cycle arrest (G2-M phase), inhibition of cytochrome c oxidase (CcO), inhibition of tumour growth and metastasis, and inhibition of tumour immune escape. Chlorpromazine hydrochloride also blocks hNa_v1.7 channels (IC₅₀=25.9 μM; concentration-dependent) and HERG potassium channels (IC₅₀=21.6 μM), which has potential for analgesic and cardiac arrhythmic studies. Chlorpromazine hydrochloride also can inhibit clathrin-mediated endocytosis .

HY-B0504S

Creatinine-d3 5 Publications Verification NSC13123-d₃	Isotope-Labeled Compounds Endogenous Metabolite iGluR GABA Receptor	Metabolic Disease Cancer
Creatinine-d₃ is a deuterium labeled Creatinine. Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure .

HY-13204A

Biperiden KL 373	mAChR	Neurological Disease
Biperiden (KL 373) is a non-selective muscarinic receptor antagonist that competitively binds to M1 muscarinic receptors, thereby inhibiting acetylcholine and enhancing dopamine signaling in the central nervous system. Biperiden has the potential for the research of Parkinson's disease and other related psychiatric disorders .

HY-B0504

Creatinine 5+ Cited Publications NSC13123	Endogenous Metabolite GABA Receptor iGluR	Infection Neurological Disease Metabolic Disease Cancer
Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure .

HY-B1487

Procyclidine hydrochloride Tricyclamol hydrochloride; (±)-Procyclidine hydrochloride	iGluR mAChR	Neurological Disease
Procyclidine (Tricyclamol, (±)-Procyclidine) hydrochloride , an anticholinergic agent, is a muscarinic receptor antagonist that also has the properties of an N-methyl-D-aspartate (NMDA) antagonist. Procyclidine hydrochloride can be used in studies of Parkinson's disease and related psychiatric disorders such as Soman-induced epilepsy .

HY-13204

Biperiden hydrochloride KL 373 hydrochloride	mAChR	Neurological Disease
Biperiden (KL 373) hydrochloride is a non-selective muscarinic receptor antagonist that competitively binds to M1 muscarinic receptors, thereby inhibiting acetylcholine and enhancing dopamine signaling in the central nervous system. Biperiden hydrochloride has the potential for the research of Parkinson's disease and other related psychiatric disorders .

HY-16716

Basmisanil 1 Publications Verification RG1662; RO5186582	GABA Receptor	Neurological Disease
Basmisanil (RG1662) is a highly selective orally active α subunit-containing GABAA receptors (GABAAα5) negative allosteric modulator (NAMs). Basmisanil can inhibit GABAA-α5 with a K_i value of 5 nM and IC₅₀ value of 8 nM, respectively. Basmisanil can be used for the research of multiple cognitive and psychiatric disorders .

HY-19733

Lumateperone tosylate ITI-007 tosylate	5-HT Receptor Dopamine Receptor	Neurological Disease Cancer
Lumateperone (ITI-007) tosylate is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a dopamine D1 receptor modulator. Lumateperone tosylate has anticancer activity and can also be used in studies of psychiatric disorders such as schizophrenia .

HY-12443

PF-5006739	Casein Kinase	Neurological Disease
PF-5006739 is a potent and selective inhibitor of CK1δ/ε with IC₅₀s of 3.9 nM and 17.0 nM, respectively. PF-5006739 is a potential therapeutic agent for a range of psychiatric disorders with low nanomolar in vitro potency for CK1δ/ε and high kinome selectivity. PF-5006739 attenuats opioid agent-seeking behavior in a rodent operant reinstatement model in animals in a dose-dependent manner . PF-5006739 improves glucose tolerance in both diet-induced obesity (DIO) and genetic (ob/ob) mice models of obesity .

HY-B0504S2

Creatinine-d5 NSC13123-d₅	Isotope-Labeled Compounds Endogenous Metabolite iGluR GABA Receptor	Metabolic Disease
Creatinine-d₅ is the deuterium labeled Creatinine. Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure .

HY-109164

Zelquistinel AGN-241751; GATE-251	iGluR	Neurological Disease
Zelquistinel (AGN-241751) is the orally active N-methyl-D-aspartate (NMDA) receptor partial agonist used for the research of depression, anxiety and other related psychiatric disorders .

HY-W250174

Lithium 3,5-diiodosalicylate 3,5-Diiodosalicylic acid lithium salt	Biochemical Assay Reagents	Others
Lithium 3,5-diiodosalicylate is a compound used in the study of bipolar disorder and other psychiatric disorders. It contains lithium and a salicylate. Lithium 3,5-diiodosalicylate works by affecting the levels of certain neurotransmitters in the brain, including dopamine and serotonin.

HY-110175

CX614 1 Publications Verification	iGluR	Neurological Disease
CX614 is a positive variant modulator of AMPA receptors that enhances excitatory postsynaptic potentials (amplitude and duration) by blocking and slowing the inactivation of responses to glutamate and automatically evokes excitatory postsynaptic currents in neuronal cultures. CX614 can be used in the study of psychiatric disorders such as depression .

HY-15522

WAY-267464 2 Publications Verification	Oxytocin Receptor	Neurological Disease
WAY-267464 is a non-peptide oxytocin receptor (OTR) agonist. WAY-267464 can impair social recognition memory in rats through a vasopressin 1A receptor antagonist action. WAY-267464 can be used for the research of psychiatric disorders, such disorders include autism spectrum disorder, schizophrenia, and social anxiety disorder .

HY-B1693

Levomepromazine 1 Publications Verification Methotrimeprazine	5-HT Receptor Dopamine Receptor Histamine Receptor Autophagy Enterovirus Calcium Channel	Infection Neurological Disease Inflammation/Immunology
Levomepromazine (Methotrimeprazine) is an orally active antipsychotic compound and Ca ²⁺ release inducer. Levomepromazine inhibits SERCA pump and induces an increase in cytoplasmic Ca ²⁺ levels. Levomepromazine has antagonistic effects on a variety of neurotransmitter receptors, including dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine can induce adaptive ER stress and autophagy. In addition, Levomepromazine has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine can be used in the study psychiatric disorders and relieving nausea and vomiting .

HY-107664

SR 142948	Neurotensin Receptor	Neurological Disease
SR 142948 is an orally active and selective non-peptide neurotensin receptor (NT) antagonist with IC₅₀s of 1.19 nM, 0.32 nM, 3.96 nM in h-NTR1-CHO cells, HT-29 cells, and adult rat brain, respectively. SR 142948 antagonizes NT-induced inositol monophosphate formation in HT-29 cells with an IC50 of 3.9 nM. SR 142948 blocks hypothermia, analgesia and steering behavior induced by NT in vivo. SR 142948 shows blood-brain permeability and can be used in study of psychiatric disorders .

HY-124607B

BRD3731 2 Publications Verification	GSK-3	Neurological Disease Metabolic Disease
BRD3731 is a selective GSK3β inhibitor, with IC₅₀s of 15 nM and 215 nM for GSK3β and GSK3α, respectively. BRD3731 is potentail for the research of post-traumatic stress disorder (PTSD), psychiatric disorder, diabetes, and neurodegenerative disorders .

HY-137790

Bicuculline methochloride 35+ Cited Publications (-)-Bicuculline methochloride	GABA Receptor	Neurological Disease
Bicuculline ((+)-Bicuculline; d-Bicuculline) methochloride is a selective GABAA receptor antagonist with an IC₅₀ value of 3 μM. Bicuculline methochloride induces clonic tonic convulsions in mammals and can also be used to block Ca ²⁺ activated potassium channels. Bicuculline methochloride can be used in studies of epilepsy and other related psychiatric disorders .

HY-13999

Amdiglurax NSI-189	Trk Receptor	Neurological Disease
Amdiglurax (NSI-189) is an orally active chemical entity with enhanced neurogenic activity. Amdiglurax up-regulates neurogenic factors such as BDNF (brain derived-neurotrophic factor) and SCF. Amdiglurax exhibits anti-depressant effect. Amdiglurax enhances synaptic plasticity and reduces cognitive dysfunction. Amdiglurax holds potential for psychiatric disorder research .

HY-B0504R

Creatinine (Standard) NSC13123 (Standard)	Reference Standards Endogenous Metabolite iGluR GABA Receptor	Metabolic Disease Cancer
Creatinine (Standard) is the analytical standard of Creatinine. This product is intended for research and analytical applications. Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure .

HY-B1482A

Mesoridazine TPS-23	Potassium Channel	Neurological Disease
Mesoridazine (TPS-23) , a metabolite of Thioridazine (HY-B0965A), acts as an orally active phenothiazine antipsychotic agent. Mesoridazine is a potent and rapid open-channel blocker of human ether-a-go-go related gene (hERG) channels and blocks hERG currents with an IC₅₀ of 550 nM (at 0 mV) in human embryonic kidney 293 cells .Mesoridazine can be used for the research of schizophrenia, as well as certain other psychiatric disorders .

HY-B0504S1

Creatinine-13C NSC13123-¹³C	Isotope-Labeled Compounds Endogenous Metabolite iGluR GABA Receptor	Metabolic Disease
Creatinine- ¹³C is the ¹³C-labeled Creatinine. Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure .

HY-P6292

KS-133	PACAP Receptor PKA ERK PI3K Akt GSK-3	Neurological Disease Cancer
KS-133 is a bicyclic peptide with VIPR2 antagonistic activity that can cross the blood-brain barrier. KS-133 selectively blocks VIPR2-mediated Gq/Ca, Gs/cAMP, cAMP/PKA/ERK and PI3K/AKT/GSK3β signaling pathways. KS-133 inhibits VIPR2 agonist-induced CREB phosphorylation in the prefrontal cortex of mice. KS-133 shifts the polarization direction of macrophages toward M1. KS-133 attenuates cancer cell proliferation and reduces the cell cycle distribution level at the S-M phase. KS-133 exerts antitumor effects in a mouse model of colorectal cancer. KS-133 reverses cognitive decline in mouse models of psychiatric disorders. KS-133 can be used for research related to schizophrenia, colorectal cancer and breast cancer .

HY-108679

WAY-267464 hydrochloride 2 Publications Verification	Oxytocin Receptor	Neurological Disease
WAY-267464 (hydrochloride) is a non-peptide oxytocin receptor (OTR) agonist. WAY-267464 (hydrochloride) can impair social recognition memory in rats through a vasopressin 1A receptor antagonist action. WAY-267464 (hydrochloride) can be used for the research of psychiatric disorders, such disorders include autism spectrum disorder, schizophrenia, and social anxiety disorder .

HY-130125

SLC1A1/EAAT3-IN-1	EAAT	Neurological Disease
SLC1A1/EAAT3-IN-1 (Compound 3e) is a selective EAAT3 inhibitor with an IC₅₀ of 7.2  μM for hEAAT3 over EAAT1,2,4 (IC₅₀: ∼ 250 μM). SLC1A1/EAAT3-IN-1 can be used for psychiatric disorders such as obsessive compulsive disorder and schizophrenia research .

HY-153530

LI-2242	IPK Superfamily	Neurological Disease Metabolic Disease
LI-2242 is an inositol hexakisphosphate kinase (IP6K) inhibitor. LI-2242 has inhibition effect for IP6K1, IP6K2, IP6K3 and IPMK with IC₅₀ values of 31 nM, 42 nM, 8.7 nM and 1944 nM, respectively. LI-2242 can be used for thew research of type II diabetes, obesity, metabolic complications, venous thrombosis, and psychiatric disorders .

HY-103429

Quinelorane dihydrochloride LY163502	Dopamine Receptor	Neurological Disease
Quinelorane dihydrochloride (LY163502) is a potent dopamine D3/D2 receptor agonist. Quinelorane has the potential for neurological and psychiatric disorders research .

HY-122805

PF-794	Ser/Thr Protease	Neurological Disease
PF-794 is a potent, selective and ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with an IC₅₀ of 39 nM. PF-794 shows selective for the TNIK family. PF-794 reduces endogenous p120-catenin phosphorylation in cells. PF-794 can be used for teh study of psychiatric disorders .

HY-175442

GluN1/3A-IN-2	iGluR	Neurological Disease
GluN1/3A-IN-2 (Compound DD-1) is a selective GluN1/GluN3A NMDA receptor inhibitor with an IC₅₀ of 1.26  μM for GluN1/GluN3A NMDA receptor. GluN1/3A-IN-2 can be used for neurological and psychiatric disorders research .

HY-13456

LY-404187	iGluR	Neurological Disease
LY-404187 is a potent, selective and centrally active positive allosteric modulator of AMPA receptors, with the EC₅₀s of 5.65, 0.15, 1.44, 1.66 and 0.21 µM for GluR1i, GluR2i, GluR2o, GluR3i and GluR4i, respectively. LY-404187 has therapeutic potential in a number of psychiatric disorders and neurodegenerative diseases .

HY-134661

(S)-CVN424	GPR6	Neurological Disease
(S)-CVN424 is a potent G-Protein-Coupled Receptor 6 (GPR6) modulator. (S)-CVN424 has the potential for a variety of neurological and psychiatric disorders research, including Parkinson's disease .

HY-117292

DAO-IN-2 1 Publications Verification	Amino Acid Oxidase	Neurological Disease
DAO-IN-2 is a d-amino acid oxidase (DAO) inhibitor (h-DAO IC₅₀ = 245 nM). DAO-IN-2 is a moderate inhibitor of DAAO in vitro and in vivo. DAO-IN-2 can be used to study DAAO-related psychiatric disorders .

HY-100783B

Bicuculline methobromide (+)-Bicuculline methobromide	GABA Receptor	Neurological Disease
Bicuculline methobromide is a selective GABAA Receptor antagonist with an IC₅₀ value of 3 μM. Bicuculline methobromide induces clonic tonic convulsions in mammals and can also be used to block Ca ²⁺ activated potassium channels. Bicuculline methobromide can be used in studies of epilepsy and other related psychiatric disorders .

HY-18078

PQ-10	Phosphodiesterase (PDE)	Neurological Disease
PQ-10 is a potent inhibitor of Phosphodiesterase 10A (PDE10A) with IC₅₀ andED₅₀ of 4.6 nM and 13 mg/kg, respectively. PQ-10 induces patterns of brain glucose metabolism which can be a potential translational biomarker. PQ-10 has the potential for researching psychiatric disorders like schizophrenia .

HY-13999A1

Amdiglurax phosphate NSI-189 phosphate	Trk Receptor	Neurological Disease
Amdiglurax (NSI-189) phosphate is an orally active chemical entity with enhanced neurogenic activity. Amdiglurax phosphate up-regulates neurogenic factors such as BDNF (brain derived-neurotrophic factor) and SCF. Amdiglurax phosphate exhibits anti-depressant effect. Amdiglurax enhances synaptic plasticity and reduces cognitive dysfunction. Amdiglurax phosphate holds potential for psychiatric disorder research .

HY-175511

5-HT2A agonist 7	5-HT Receptor	Neurological Disease
5-HT2A agonist 7 (Compound 45) is an orally active and highly selective serotonin receptor 2A (5-HT_2A) agonist (EC₅₀=12 nM). 5-HT2A agonist 7 is promising for research of psychiatric disorders such as depression .

HY-101490

PDE1-IN-2	Phosphodiesterase (PDE)	Neurological Disease
PDE1-IN-2 is a PDE1 inhibitor extracted from patent WO2016/55618 A1, example 31. PDE1-IN-2 has IC₅₀ values of 6 nM, 140 nM and 164 nM for PDE1C, PDE1B and PDE1A, respectvely. PDE1-IN-2 is developed for the research of neurodegenerative disorders and psychiatric disorders .

HY-148325

α7 Nicotinic receptor agonist-1	nAChR	Neurological Disease
α7 Nicotinic receptor agonist-1 (Preparation 5) is an α7 nAChR agonist. α7 Nicotinic receptor agonist-1 can be used in studies of psychiatric disorders (such as schizophrenia, manic or hypomanic depression and anxiety disorders) and intellectual disorders (such as alzheimer's disease, learning deficits, cognitive deficits, attention deficits, memory loss, lewy body dementia and attention deficit hyperactivity disorder) .

HY-B0504S5

Creatinine-15N NSC13123-¹⁵N	Isotope-Labeled Compounds Endogenous Metabolite iGluR GABA Receptor	Metabolic Disease Cancer
Creatinine- ¹⁵N (NSC13123- ¹⁵N) is the ¹⁵N-labeled Creatinine (HY-B0504). Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure .

HY-A0243

Aceprometazine 1664CB; Acepromethazine	Histamine Receptor	Neurological Disease
Aceprometazine (1664CB) is an orally active antipsychotic. Aceprometazine can be used in the study of psychiatric disorders, such as depression .

HY-101841

LY 2033298	mAChR	Neurological Disease
LY 2033298 is a selective positive allosteric modulator of the muscarinic M₄ receptor. LY 2033298 can be used in the study of psychiatric disorders .

HY-156817

TNIK-IN-6	TNF Receptor	Neurological Disease
TNIK-IN-6 (Compound 9) is an inhibitor of Traf2 and Nck-interacting kinase (TNIK) and , with IC₅₀ of 0.93 μM, that plays important roles in neurological and psychiatric disorders .

HY-W773779

GSK3-IN-9	GSK-3	Neurological Disease Metabolic Disease Cancer
GSK3-IN-9 (Compound 0713) is a selective glycogen synthase kinase 3 (GSK3) inhibitor. GSK3-IN-9 Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder .

HY-B1487R

Procyclidine hydrochloride (Standard) Tricyclamol hydrochloride (Standard); (±)-Procyclidine hydrochloride (Standard)	Reference Standards iGluR mAChR	Neurological Disease
Procyclidine (hydrochloride) (Standard) is the analytical standard of Procyclidine (hydrochloride). This product is intended for research and analytical applications. Procyclidine (Tricyclamol, (±)-Procyclidine) hydrochloride , an anticholinergic agent, is a muscarinic receptor antagonist that also has the properties of an N-methyl-D-aspartate (NMDA) antagonist. Procyclidine hydrochloride can be used in studies of Parkinson's disease and related psychiatric disorders such as Soman-induced epilepsy .

HY-116076

S-15535	5-HT Receptor	Neurological Disease
S-15535 is a highly selective 5-HT_1A receptor ligand. S-15535 is an antagonist of postsynaptic 5-HT_1A receptors and an agonist of presynaptic 5-HT_1A receptors. S-15535 can be used in research on psychiatric disorders, such as anti-anxiety .

HY-161511

LPH-5	5-HT Receptor	Neurological Disease
LPH-5 is a selective 5-HT2A receptor agonist (EC₅₀=190 nM). LPH-5 works by selectively activating the 5-HT2A receptor, which may be involved in regulating mood, perception, and other central nervous system functions associated with the 5-HT2A receptor. LPH-5 can be used to further explore the 5-HT2A receptor in psychiatric disorders, including depression, anxiety, and substance abuse disorders .

HY-107664A

SR 142948 dihydrochloride	Neurotensin Receptor	Neurological Disease
SR 142948 dihydrochloride is an orally active and selective non-peptide neurotensin receptor (NT) antagonist with IC₅₀s of 1.19 nM, 0.32 nM, 3.96 nM in h-NTR1-CHO cells, HT-29 cells, and adult rat brain, respectively. SR 142948 dihydrochloride antagonizes NT-induced inositol monophosphate formation in HT-29 cells with an IC₅₀ of 3.9 nM. SR 142948 dihydrochloride blocks hypothermia, analgesia and steering behavior induced by NT in vivo. SR 142948 dihydrochloride shows blood-brain permeability and can be used in study of psychiatric disorders .

HY-118635

Cyprodenate Actebral	Radionuclide-Drug Conjugates (RDCs)	Neurological Disease
Cyprodenate is an orally active and blood-brain barrier-penetrant stimulant. Cyprodenate can be labeled with ¹⁴C. Cyprodenate can be used in the research of psychiatric disorders .

HY-137161

6-Nitroquipazine DU24565	Serotonin Transporter	Neurological Disease
6-Nitroquipazine (DU24565) is a potent and selective 5-HT transporter inhibitor, with a K_i of 0.17 nM. 6-Nitroquipazine can be used in the research of psychiatric disorders such as depression .

Cat. No.	Product Name	Target	Research Area

HY-P6292

KS-133	PACAP Receptor PKA ERK PI3K Akt GSK-3	Neurological Disease Cancer
KS-133 is a bicyclic peptide with VIPR2 antagonistic activity that can cross the blood-brain barrier. KS-133 selectively blocks VIPR2-mediated Gq/Ca, Gs/cAMP, cAMP/PKA/ERK and PI3K/AKT/GSK3β signaling pathways. KS-133 inhibits VIPR2 agonist-induced CREB phosphorylation in the prefrontal cortex of mice. KS-133 shifts the polarization direction of macrophages toward M1. KS-133 attenuates cancer cell proliferation and reduces the cell cycle distribution level at the S-M phase. KS-133 exerts antitumor effects in a mouse model of colorectal cancer. KS-133 reverses cognitive decline in mouse models of psychiatric disorders. KS-133 can be used for research related to schizophrenia, colorectal cancer and breast cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0504

Creatinine 5+ Cited Publications NSC13123	Infection Structural Classification Natural Products Classification of Application Fields Disease markers Endocrine diseases Metabolic Disease Nervous System Disorder Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite GABA Receptor iGluR
Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure .

HY-B0504R

Creatinine (Standard) NSC13123 (Standard)	Infection Structural Classification Natural Products Microorganisms Disease markers Endocrine diseases Nervous System Disorder Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite iGluR GABA Receptor
Creatinine (Standard) is the analytical standard of Creatinine. This product is intended for research and analytical applications. Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure .

HY-113969

7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	Alkaloids Neurological Disease Classification of Application Fields Endogenous metabolite Isoquinoline Alkaloids Disease Research Fields Source Classification	Endogenous Metabolite
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline (compound 11), a tetrahydroisoquinoline (THIQ) derivative, is a selective phenylethanolamine N-methyltransferase (PNMT) inhibitor with a K_i value of 0.3 μM. 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline can be used in research on psychiatric disorders related to Alzheimer's disease and Parkinson's disease .

HY-W041470R

4-Methyl-1-phenyl-2-pentanone (Standard)	Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Chlorpromazine (hydrochloride) (Standard) is the analytical standard of Chlorpromazine (hydrochloride). This product is intended for research and analytical applications. Chlorpromazine hydrochloride is an orally active, blood-brain barrier-transparent antipsychotic agent that effectively antagonises D2 dopamine receptors and 5-HT2A, which is widely used in schizophrenia and other psychiatric disorders. Chlorpromazine hydrochloride exerts anti-cancer activity through a variety of pathways, including anti-proliferation, induction of autophagy and cycle arrest (G2-M phase), inhibition of cytochrome c oxidase (CcO), inhibition of tumour growth and metastasis, and inhibition of tumour immune escape. Chlorpromazine hydrochloride also blocks hNav1.7 channels (IC50=25.9 μM; concentration-dependent) and HERG potassium channels (IC50=21.6 μM), which has potential for analgesic and cardiac arrhythmic studies. Chlorpromazine hydrochloride also can inhibit clathrin-mediated endocytosis .

Cat. No.	Product Name	Chemical Structure

HY-B0504S

Creatinine-d3

5 Publications Verification

Creatinine-d₃ is a deuterium labeled Creatinine. Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure .

HY-B0504S2

Creatinine-d5

Creatinine-d₅ is the deuterium labeled Creatinine. Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure .

HY-B0504S1

Creatinine-13C

Creatinine- ¹³C is the ¹³C-labeled Creatinine. Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure .

HY-B0504S5

Creatinine-15N

Creatinine- ¹⁵N (NSC13123- ¹⁵N) is the ¹⁵N-labeled Creatinine (HY-B0504). Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure .

HY-B1487S1

Procyclidine-d5

Procyclidine-d₅ (Tricyclamol-d₅) is deuterium labeled Procyclidine (hydrochloride). Procyclidine (Tricyclamol, (±)-Procyclidine) hydrochloride , an anticholinergic agent, is a muscarinic receptor antagonist that also has the properties of an N-methyl-D-aspartate (NMDA) antagonist. Procyclidine hydrochloride can be used in studies of Parkinson's disease and related psychiatric disorders such as Soman-induced epilepsy .

HY-13204AS

Biperiden-d5
Biperiden-d₅ (KL 373-d₅) is deuterium labeled Biperiden. Biperiden (KL 373) is a non-selective muscarinic receptor antagonist that competitively binds to M1 muscarinic receptors, thereby inhibiting acetylcholine and enhancing dopamine signaling in the central nervous system. Biperiden has the potential for the research of Parkinson's disease and other related psychiatric disorders .

HY-B1482AS

Mesoridazine-d3

Mesoridazine-d₃ is the deuterium labeled Mesoridazine (HY-B1482A). Mesoridazine (TPS-23) , a metabolite of Thioridazine (HY-B0965A), acts as an orally active phenothiazine antipsychotic agent. Mesoridazine is a potent and rapid open-channel blocker of human ether-a-go-go related gene (hERG) channels and blocks hERG currents with an IC₅₀ of 550 nM (at 0 mV) in human embryonic kidney 293 cells .Mesoridazine can be used for the research of schizophrenia, as well as certain other psychiatric disorders .

HY-19733S

Lumateperone-13C,d3 tosylate

Lumateperone- ¹³C,d₃ (ITI-007- ¹³C,d₃) tosylate is ¹³C and deuterium labeled Lumateperone (tosylate). Lumateperone (ITI-007) tosylate is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a dopamine D1 receptor modulator. Lumateperone tosylate has anticancer activity and can also be used in studies of psychiatric disorders such as schizophrenia .

HY-166562S

Levomepromazine-d6 hydrochloride

Levomepromazine-d₆ hydrochloride (Methotrimeprazine-d₆ hydrochloride) is the deuterium labeled Levomepromazine hydrochloride. Levomepromazine (Methotrimeprazine) hydrochloride is an orally active antipsychotic compound and Ca ²⁺ release inducer. Levomepromazine inhibits SERCA pump and induces an increase in cytoplasmic Ca ²⁺ levels. Levomepromazine hydrochloride has antagonistic effects on a variety of neurotransmitter receptors, including dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine hydrochloride can induce adaptive ER stress and autophagy. In addition, Levomepromazine hydrochloride has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine hydrochloride can be used in the study psychiatric disorders and relieving nausea and vomiting .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks